LTβR agonist alone no change in TA-HEV tumour area in MMTv-PyMT and no impact on tumour cell death and proliferationNeither LTβR activation alone nor anti- angiogenic/PD-L1 blockade therapy affected tumour growth, but the combination of both treatment modalities reduced tumour burden by more than 60%. The gene discussed is LTBR; the disease is neoplasm.